Status:
COMPLETED
The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients
Lead Sponsor:
Samsung Medical Center
Conditions:
Interstitial Cystitis
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
The efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate after transurethral resection of Hunner lesion in interstitial cystitis/bladder pain syndrome patients. To analyze the n...
Eligibility Criteria
Inclusion
- Male and female aged 20 yrs or greater
- Patients diagnosed with Hunner lesion in IC(interstitial cystitis)/BPS(Bladder Pain Syndrome) and who is scheduled to undergo transurethral resection
- Symptom persisted more than 6 months
- Pain VAS ≥4
Exclusion
- History of augmentation cystoplasty or previous transurethral coagulation/resection due to IC/BPS
- Child-bearing potential, pregnant or nursing women.
- Hematuria exceeds 1+ in the urinary dipstick (dipstick) examination.
- Urinary tract infection during run-in periods.
- Genitourinary tuberculosis or bladder,urethral and prostate cancer
- Recurrent urinary tract infection
- History of hysterectomy,mid-urethral sling,pelvic organ prolapse repair,vaginal delivery or Cesarean section,prostate operation or treatment etc within 6months.
- Neurologic disease history of cerebral infarction,multiple sclerosis or parkinsonism etc.-
- Using a indwelling catheter or execution of intermittent self catheterization
Key Trial Info
Start Date :
September 22 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT03463499
Start Date
September 22 2017
End Date
December 31 2021
Last Update
October 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center, Sungkyunkwan University School of Medicine
Seoul, South Korea, 135-710